Amben - instructions for use, doses, side effects, contraindications

Active substanceAminomethylbenzoic acidAminomethylbenzoic acid

Similar drugsTo uncover

Amben

solution w / m in / in

FARMZASCHITA NPC, GP Russia

Pamba

solution w / m in / in

PROFIT FARM, LLC Russia

Dosage form: & nbsp

solution for intravenous and intramuscular administration

Composition:

Per 1 ml:

Active substance: Ambene (in terms of anhydrous substance) 10 mg.

Excipients: sodium chloride 9 mg, water for injection up to 1 ml.

Description:

Colorless transparent liquid.

Pharmacotherapeutic group:Hemostatic agent

ATX: & nbsp

B.02.A.A.03 Aminomethylbenzoic acid

Pharmacodynamics:

AMBEN refers to inhibitors of fibrinolysis, synthetic analogues of lysine. By its action is analogous to epsilon-aminocaproic acid, however it is much more effective than it. The specific hemostatic effect of AMBENA in bleeding due to increased fibrinolysis is associated with blockade of plasminogen activators and partial inhibition of plasmin. AMBEN inhibits fibrinolysis, competitively saturating the lysine-binding receptors, through which plasminogen (plasmin) binds to fibrinogen (fibrin). The drug also inhibits biogenic polypeptides-kinins.

AMBEN enhances detoxifying function of the liver, inhibits antigenigenesis.

Pharmacokinetics:

With internal administration, the maximum concentration of the drug in the blood is determined immediately after administration and lasts up to 3 hours. AMBEN is excreted from the body by the kidneys: 60% -80% unchanged. If the excretory function of the kidneys is disturbed, the concentration of AMBEN in the blood increases significantly.

Indications:

- The conditions under which systemic hyperfibrinolysis develops (overdose of plasminogen activators: streptokinase, urokinase, etc.);

- with a decrease in the ability to form a hemostatic thrombus (with a violation of procoagulant, platelet or vascular components of hemostasis);

- with localized hemorrhages due to increased local fibrinolytic activity (after tonsillectomy, operations on the prostate, bladder, menorrhagia).

- with surgical operations and various pathological processes with increased fibrinolytic activity of the blood; operations on the brain (including, with subarachnoid hemorrhages), operations on the lungs, heart, vessels, thyroid and pancreas; after dental interventions, with premature detachment of the normally located placenta,prolonged retention in the uterine cavity of the dead fetus, uterine bleeding; with acute pancreatitis; liver diseases; nasal, gastrointestinal bleeding.

- prevention of the development of secondary hypophybrinogenemia in massive transfusions of canned blood.

Contraindications:

Tendency to thrombosis and thromboembolic diseases, hypersensitivity, hypercoagulable phase of DIC syndrome, vitreous hemorrhage, severe forms of coronary heart disease and cerebral ischemia, with kidney disease with impaired function.

Carefully:

Use with caution in cases of cerebral circulation disorders!

Pregnancy and lactation:

In preclinical studies aminomethylbenzoic acid did not have a teratogenic effect on animals. The use of Amben in the first trimester of pregnancy is contraindicated. The use of the drug on late pregnancy and in the period of breastfeeding is possible only in case of emergency and with extreme caution.

Dosing and Administration:

Enter intramuscularly or intravenously struino in doses of 50-100 mg (5-10 ml of a solution of 10 mg / ml).If necessary, the introduction can be repeated many times with intervals of not less than 4 hours. In acute fibrinolysis, fibrinogen is additionally administered, controlling the fibrinolytic activity of the blood and the content of fibrinogen in it. The maximum single dose of the drug is 100 mg (10 ml of a solution of 10 mg / ml). The total (daily) dose and duration of treatment depend on the course of the disease.

Side effects:

From the digestive system: vomiting, diarrhea.

On the part of the CAS: increase or decrease in blood pressure, tachycardia.

Local Reactions: thrombophlebitis at the injection site.

Allergic reactions.

Other: renal colic, catarrhal phenomena from the upper respiratory ways.

In some cases, dizziness, orthostatic hypotension, convulsions are observed. In this case, you should reduce the dose or cancel the drug.

Overdose:

An overdose of the drug is extremely rare and is characterized by increased blood coagulability. In case of an overdose, intravenous administration of heparin at a dose of 5000 ME and / or cancellation of the drug.

Interaction:

Simultaneous application of large doses of Amben and other haemostatic agents (eg.etamzilate) can lead to the formation of thrombi, on the one hand, due to the enhancement of fibrin formation under the influence of hemostatics, and on the other hand, due to the slow dissolution of thrombi due to the antiplasmin action of Amben.

Special instructions:

The purpose of the drug requires checking the fibrinolytic activity of the blood and the level of fibrinogen. With intravenous administration, coagulogram monitoring is necessary, especially in coronary heart disease, after myocardial infarction, in diseases liver.

Introduction AMBENA can be combined with the introduction of hydrolysates, especially glucose solution, anti-shock solutions. In acute fibrinolysis, fibrinogen is additionally administered (the average dose of the latter is 2 to 4 g, the maximum dose is 8 g).

Effect on the ability to drive transp. cf. and fur:

Data on the adverse effect of the drug on the ability to manage vehicles and mechanisms are absent.

Form release / dosage:

Solution for intravenous and intramuscular injection 10 mg / ml.

Packaging:In ampoules of 5 ml. 5 ampoules per contour cell pack of polyvinyl chloride film.2 contour squares with instructions for use in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

3 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N000456 / 01

Date of registration:19.01.2009 / 05.11.2013

Expiration Date:Unlimited

The owner of the registration certificate:FARMZASCHITA NPC, GP FARMZASCHITA NPC, GP Russia

Manufacturer: & nbsp

FARMZASCHITA NPC, FSUE Russia

Information update date: & nbsp27.07.2017

Illustrated instructions

Instructions

Amben (Amben)